Frontlight ResearchEarly access
CompletedNo phase
Esketamine on Postpartum Depression in Cesarean Section Women
Key facts
- Who runs it
- Ailin Luo
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 336 people enrolled
- Started
- 1 May 2021
- Ended
- 31 Mar 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Esketamine
- Normal saline
- Record updated
- 6 August 2024
Who can take part
- Age
- 18 years to 40 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Elective cesarean section
- 18-40 years
- Primipara
- Singleton pregnancy
- Sign informed consent
Who cannot take part
- Drug abuse and alcoholism
- Intracranial hypertension
- Hypertension
- Severe heart disease
- Mental disorder, mental retardation
- American Society of Anesthesiologists (ASA) grade III and above
- Hyperthyroidism patients without treatment or insufficient treatment
- Liver and kidney dysfunction
- Preeclampsia or eclampsia
- Contraindication of intraspinal anesthesia
- The preoperative EPDS score ≥10
- Participated in other clinical studies
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study was to explore the preventive effect of esketamine on postpartum depression (PPD) in cesarean section, and to evaluate the safety of the drug
The 2 groups in the trial
- N groupPlacebo, for comparison
15 minutes after umbilical cord amputation, the patient was intravenously injected with 10 ml normal saline
Treatment: Normal saline
- Es groupTreatment being tested
15 minutes after umbilical cord amputation, the patient was intravenously injected with 0.25mg/kg esketamine, PCIA regimen: sufentanil 100 μ g, esketamine 80 mg, diluted to 100 ml with 0.9% normal saline, set analgesia pump background infusion dose 2 ml/h, single bolus dose 2 ml, locking time 8 minutes.
Treatment: Esketamine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Prophylactic Esketamine on Postpartum Depression in Cesarean Section: A Multicenter, Prospective, Randomized, Controlled Study
- Publications
- Prophylactic esketamine to reduce postpartum depression in primiparae: A multicentre, double-blind, randomised clinical trial.European journal of anaesthesiology, 2026
- Record updated
- 6 August 2024